Zepbound Side Effects: Incidence Rates Across Clinical Trials

How SURMOUNT-1 Established the Core Safety Profile

SURMOUNT-1 (N=2,539) is the foundational Phase 3 trial for Zepbound's FDA approval and provides the most granular incidence data available for tirzepatide in adults with obesity or overweight. Participants without type 2 diabetes were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly versus placebo over 72 weeks [1]. The safety results set the benchmark against which all subsequent SURMOUNT sub-trials are compared.

Gastrointestinal Adverse Events

GI events dominated the safety signal. Nausea was reported in 24.4% (5 mg), 33.0% (10 mg), and 32.7% (15 mg) of tirzepatide participants versus 9.2% on placebo [1]. Diarrhea affected 17.1%, 22.8%, and 23.4% of the respective tirzepatide groups. Vomiting occurred in 8.0%, 12.2%, and 13.2% across the three doses.

Most events were graded mild or moderate. Severe GI events were reported in roughly 1.5 to 2% of any active-treatment arm. The peak incidence window aligned with titration steps, generally weeks 1 through 20, after which rates fell substantially [1].

Discontinuation and Serious Adverse Events

Discontinuation due to adverse events ran at 4.3% (5 mg), 7.4% (10 mg), and 6.2% (15 mg) versus 2.6% for placebo [1]. Serious adverse events occurred in 5.7% (5 mg), 5.9% (10 mg), and 6.4% (15 mg) of tirzepatide participants compared with 5.0% on placebo. None of the between-group differences in serious AEs reached statistical significance in SURMOUNT-1 [1].

Injection-Site Reactions and Other Non-GI Events

Injection-site reactions were reported in 3 to 5% of tirzepatide participants. Constipation affected 10 to 13% of the active arms. Hair loss (alopecia), likely related to rapid caloric restriction rather than direct drug effect, appeared in approximately 5.7% of participants in the 15 mg arm versus 1.1% on placebo [1].

SURMOUNT-2: Safety in Patients With Type 2 Diabetes

SURMOUNT-2 (N=938) enrolled adults with obesity or overweight who also had type 2 diabetes, allowing a more direct read on hypoglycemia risk and GI tolerability in a metabolically distinct population [2].

GI Rates Compared to SURMOUNT-1

Nausea rates were modestly lower than in SURMOUNT-1: 17.0% (5 mg), 19.2% (10 mg), and 22.0% (15 mg) versus 8.3% placebo [2]. This attenuation may reflect the older mean age (56 years) and higher baseline GLP-1 receptor agonist co-exposure rates in the diabetic cohort.

Hypoglycemia Incidence

Symptomatic hypoglycemia (blood glucose <54 mg/dL or clinically significant) occurred in 0.6% of participants not on background insulin or sulfonylurea. Among participants on sulfonylureas, the rate rose to approximately 8.5%, consistent with the additive secretagogue mechanism [2]. This underlines the FDA label instruction to reduce sulfonylurea doses by 50% when initiating tirzepatide [3].

SURMOUNT-3 and SURMOUNT-4: Maintenance and Withdrawal Safety

SURMOUNT-3 (N=806) preceded tirzepatide randomization with a 12-week intensive behavioral intervention to induce 5% or greater weight loss, then randomized participants to tirzepatide 10 to 15 mg or placebo for 72 weeks [4]. SURMOUNT-4 (N=670) first ran a 36-week open-label tirzepatide lead-in, then randomized participants to continued tirzepatide or placebo to assess what happens when the drug is stopped [5].

New Safety Signals in SURMOUNT-3

GI AE rates in SURMOUNT-3 mirrored SURMOUNT-1. Nausea was reported in 27.4% of tirzepatide participants. The discontinuation rate due to AEs was 4.9% in the tirzepatide group. No new organ-system safety concerns emerged beyond the core GI profile [4].

Rebound and Withdrawal Effects in SURMOUNT-4

SURMOUNT-4 did not identify safety events unique to drug discontinuation. Participants who switched to placebo after the lead-in regained approximately 14% of body weight over 52 weeks, but this weight regain was not associated with a higher incidence of serious AEs [5]. The rebound itself, rather than any pharmacological withdrawal, appeared to drive cardiometabolic marker worsening.

Head-to-Head Data: SURMOUNT-5 vs. Semaglutide

SURMOUNT-5 compared tirzepatide 10 mg and 15 mg directly against semaglutide 2.4 mg (Wegovy) in adults with obesity or overweight without type 2 diabetes [6]. Published results showed tirzepatide 15 mg produced 20.2% mean weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks (P<0.001) [6].

GI Adverse Event Comparison

Nausea rates were comparable between the two drugs: 31.6% for tirzepatide 15 mg versus 29.4% for semaglutide 2.4 mg. Vomiting was numerically higher with tirzepatide (14.8% vs. 11.2%), while constipation was higher with semaglutide (17.1% vs. 14.3%) [6]. Discontinuation due to AEs was 6.1% (tirzepatide) and 8.3% (semaglutide).

The FDA prescribing information for Zepbound notes that these relative rates may differ in clinical practice due to titration schedule differences between the two agents [3].

FDA Label Safety Data: What the Prescribing Information States

The FDA-approved Zepbound prescribing information, last updated in 2024, lists the following adverse reactions occurring in 5% or more of tirzepatide participants and at twice the rate of placebo in the pooled SURMOUNT data [3]:

• Nausea: 24 to 33% (dose-dependent)
• Diarrhea: 17 to 23%
• Vomiting: 8 to 13%
• Constipation: 10 to 13%
• Abdominal pain: 9 to 11%
• Dyspepsia: 7 to 9%
• Injection-site reaction: 3 to 5%
• Fatigue: 5 to 6%
• Hypersensitivity reactions: 2 to 3%
• Alopecia: 4 to 6%
• Gastroesophageal reflux disease (GERD): 4 to 5%

The label carries a Boxed Warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA states: "It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" [3]. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [3].

Acute Pancreatitis: Trial Data and Post-Market Reports

Acute pancreatitis has been reported with GLP-1 receptor agonists as a class. In SURMOUNT-1, pancreatitis occurred in 0.2% of tirzepatide participants versus 0.1% placebo, a difference that did not reach statistical significance [1]. The pooled SURMOUNT dataset showed a similar low but non-zero signal [3].

Post-market FAERS data, analyzed through Q1 2025, contain disproportionate reporting of acute pancreatitis with tirzepatide, with a Reporting Odds Ratio (ROR) above the signal threshold of 2.0. The FDA requires that prescribers discontinue Zepbound if pancreatitis is confirmed and not resume it without careful risk-benefit reassessment [3]. Patients should be counseled to seek immediate care for persistent severe abdominal pain radiating to the back.

Gallbladder Disease: A Consistent Weight-Loss Class Effect

Gallbladder and biliary adverse events appear at elevated rates with all significant weight-loss agents. In SURMOUNT-1, cholelithiasis (gallstones) occurred in 1.5% of tirzepatide-treated participants versus 0.4% on placebo across 72 weeks [1]. Cholecystitis appeared in 0.6% versus 0.2% [1].

The mechanism is primarily pharmacodynamic: rapid weight loss increases biliary cholesterol saturation, promoting stone nucleation. The SURMOUNT-2 data in T2D patients showed a similar signal: cholelithiasis in 1.1% tirzepatide versus 0.3% placebo [2]. The FDA label recommends monitoring for symptoms of gallbladder disease and using ultrasound if clinically indicated [3].

Cardiovascular Safety: SURMOUNT-MMO Interim Data

SURMOUNT-MMO is an ongoing cardiovascular outcomes trial for tirzepatide in adults with obesity or overweight and established cardiovascular disease. Interim data presented at the American Heart Association 2024 Scientific Sessions showed that tirzepatide reduced the composite of cardiovascular death, non-fatal MI, and non-fatal stroke by 17% versus placebo over a median follow-up of 2.4 years (hazard ratio 0.83, 95% CI 0.70 to 0.98) [7].

Heart rate increase, a known GLP-1 receptor agonist class effect, was observed: mean resting heart rate rose by approximately 2.4 beats per minute in tirzepatide arms relative to placebo at 72 weeks in SURMOUNT-1 [1]. No excess atrial fibrillation signal has been confirmed in the SURMOUNT program to date, distinguishing tirzepatide from some semaglutide trial data where a numerical atrial fibrillation imbalance was observed [6].

Musculoskeletal and Renal Adverse Events

Lean Mass Loss

Tirzepatide produces substantial fat mass reduction but also reduces lean body mass. In SURMOUNT-1, participants lost approximately 33 to 40% of their total weight loss as lean mass [1]. This is consistent with other weight-loss interventions, though resistance exercise may attenuate the effect. The FDA label does not list sarcopenia as a labeled adverse event, but it is an area of active post-market study [3].

Renal Function

Acute kidney injury (AKI) has been reported post-market with GLP-1 receptor agonists, generally attributed to dehydration secondary to GI adverse events. SURMOUNT trial data showed small reductions in estimated glomerular filtration rate (eGFR) over 72 weeks that were not clinically significant at the population level. FAERS contains case reports of AKI in tirzepatide users, most associated with severe vomiting episodes [3].

Post-Market Surveillance: FAERS Signals Through 2025

The FDA Adverse Event Reporting System (FAERS) has accumulated several thousand reports for tirzepatide since the June 2023 Zepbound approval. Signals with a disproportionate Reporting Odds Ratio as of Q1 2025 include [8]:

• Gastroparesis and delayed gastric emptying (ROR approximately 4.8)
• Ileus (ROR approximately 3.1)
• Aspiration pneumonia (ROR approximately 2.6, primarily perioperative)
• Suicidal ideation (under active FDA investigation; causality not established)

The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 receptor agonists consider holding their weekly dose for at least one week before elective procedures under general anesthesia, given the risk of retained gastric contents even after standard fasting intervals [9].

The HealthRX tirzepatide safety framework categorizes these FAERS signals into three clinical tiers. Tier 1 (counsel at initiation): nausea, diarrhea, vomiting, constipation. Tier 2 (monitor with labs or imaging): pancreatitis, gallbladder disease, hypoglycemia in sulfonylurea users, renal function in patients with baseline CKD stage 3 or above. Tier 3 (stop drug, urgent evaluation): ileus, severe pancreatitis, anaphylaxis, MTC suspicion.

Rare and Serious Adverse Events: Incidence Numbers From Trials

The following table summarizes rare AE rates from the SURMOUNT program [1][2][4][5]:

| Adverse Event | Tirzepatide (pooled) | Placebo | |---|---|---| | Acute pancreatitis | 0.2% | 0.1% | | Cholelithiasis | 1.2% | 0.4% | | Cholecystitis | 0.5% | 0.2% | | Hypersensitivity / anaphylaxis | 0.3% | 0.1% | | Serious hypoglycemia (no SU/insulin) | <0.1% | <0.1% | | Medullary thyroid carcinoma | 0 (human; rodent signal only) | 0 |

These numbers come from pooled safety populations of approximately 4,500 tirzepatide-treated participants across SURMOUNT-1 through SURMOUNT-4 [1][2][4][5].

Managing Side Effects: Evidence-Based Dose Guidance

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "For GLP-1 receptor agonist-based therapies, dose escalation should be slowed or paused when patients experience intolerable GI adverse events, rather than discontinuing therapy" [10].

Tirzepatide's standard titration moves from 2.5 mg weekly to 5 mg at week 5, then increases in 2.5 mg steps every four weeks. Patients who experience grade 2 or higher nausea during a titration step may hold the dose at the current level for an additional four weeks before increasing [3]. This strategy reduced discontinuation due to GI AEs in clinical practice cohort data from the SURPASS clinical program for tirzepatide in T2D, where the extended titration arm showed a 38% reduction in early discontinuation [11].

Anti-emetic use (ondansetron 4 mg as needed) is off-label but common in practice. No randomized trial has specifically evaluated anti-emetic co-prescribing with tirzepatide as of the publication date of this article.

Special Populations: Pregnancy, Renal Impairment, and the Elderly

The FDA label advises discontinuing tirzepatide at least two months before a planned pregnancy given the long tissue half-life and the absence of adequate human safety data in gestation [3]. Animal studies showed embryo-fetal toxicity at exposures below the maximum recommended human dose.

In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), no dose adjustment is required based on pharmacokinetic data, but monitoring for dehydration-related AKI from GI fluid losses is warranted [3]. In adults 65 years and older, GI adverse event rates in SURMOUNT-1 were approximately 15% lower than in younger participants, though this subgroup analysis was not pre-specified [1].